Phase 4 N=59 Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
Atrial Fibrillation
Primary: Number of Days on Anticoagulation — 24.9 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=441 Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation After Cryptogenic Stroke
Cryptogenic Symptomatic Transient Ischemic Attack · Cryptogenic Ischemic Stroke
Primary: AF Detection Rate Within 6 Months — 8.9; 1.4 percentage of participants — p=0.0006
N/A N=321 Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation
Heart Failure · Recurrent Atrial Fibrillation
Primary: All Hospital Episodes (Emergency Room or Patient Request for OPD) Related to Treatment for Atrial Arrhythmia — 19; 76; 23 Participants — p=<0.0001
N/A N=492 Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin
Stroke, Acute
Primary: The Rate of AF Through 12 Months in Subjects With a Recent Ischemic Stroke of Presumed Known Origin. — 12.5; 1.8 percentage of participants — p=<0.001
N/A N=10 Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation
Atrial Fibrillation
Primary: Real-time Electrogram Morphology Recurrence (EMR) Mapping Feasibility — 10 Participants
N/A N=140 A New Operation for the Treatment for Long-standing Atrial Fibrillation
Cardiovascular Disease
Primary: Numbers of Participants Free From AF — 20; 96; 20; 97 Participants
Phase 3 N=127 First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)
Atrial Fibrillation
Primary: Number of Participants With Recurrence of Atrial Tachyarrhythmia — 36; 44 Participants — p=0.0016
N/A N=38 Assessing Arrhythmias After Ablation Using Implantable Recorders
Atrial Fibrillation
Primary: Arrhythmia Burden — 7; 18; 18; 5 Participants
N/A N=25 Atrial Fibrillation Recurrence in Sleep Apnea
Sleep Apnea · Atrial Fibrillation
Primary: Number of Subjects Who Had Atrial Fibrillation Recurrence at 1 Year — 3; 3 participants
N/A N=55 Hybrid Ablation Plus Medical Therapy for Persistent Atrial Fibrillation
Persistent Atrial Fibrillation
Primary: Atrial Fibrillation (AF) Burden Defined as the Mean Amount of Time Spent in AF Over a Pre-specified Period of Time (Excluding Short AF Episodes of ≤30 Seconds) by the…
Phase 4 N=676 Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
Atrial Fibrillation
Primary: Incidence of Major Bleeding Events (MBEs), as Defined by the International Society on Thrombosis and Haemostasis (ISTH) — 1.6; 6.9 percentage of participants — p=0.0009
Phase 2 N=47 Medtronic Reveal XT Study
Atrial Fibrillation
Primary: Number of ATA (Atrial Tachyarrhythmias) Episodes and Burden, Determined at Defined Postoperative Intervals — 20,878; 1,034 ATA episodes
Phase 4 N=190 Evaluating the Effectiveness of Fish Oil Supplements at Reducing the Recurrence of Atrial Fibrillation
Atrial Fibrillation
Primary: Documented Recurrence of Atrial Fibrillation/Atrial Flutter — 59; 47 percentage of participants
N/A N=24 Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
Persistent Atrial Fibrillation · Longstanding Persistent Atrial Fibrillation
Primary: Primary Safety Endpoint — 0; 0; 4.2; 0 percentage of participants
N/A N=31 Characterising the Stable and Dynamic Left Atrial Substrate in Atrial Fibrillation
Atrial Fibrillation
Primary: To Define the Normal Range of Voltage Amplitude — 2.00; 1.92 mV
Phase 4 N=24 Atrial Fibrillation Without Hemodynamic Instability in the Intensive Care Unit
Atrial Fibrillation
Primary: Conversion From Atrial Fibrillation to Sinus Rhythm — 8; 5 participants
N/A N=41 Curing Atrial Fibrillation in Heart Failure
Chronic Heart Failure · Atrial Fibrillation
Primary: Change in Left Ventricular Ejection Fraction by Magnetic Resonance Imaging (MRI)% — 2.8; 4.5 percentage of blood ejected in one beat
Phase 4 N=119 Corticosteroid Pulse After Ablation
Atrial Fibrillation
Primary: Number of Participants With Clinically Significant Atrial Arrhythmias at 6 Weeks — 4; 12 Participants
Phase 3 N=210 Tailored Treatment of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Chronic Effectiveness — 56; 26 percentage of participants with success — p=<0.0001
N/A N=53 Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke
Ischemic Stroke
Primary: Incidence of Paroxysmal Atrial Fibrillation (AF) in Ischemic Stroke Patients — 6 Participants
N/A N=109 Effect of Treatment of Sleep Apnea in Patients With Paroxysmal Atrial Fibrillation
Sleep Disordered Breathing · Sleep Apnea · Paroxysmal Atrial Fibrillation
Primary: Change in AF Burden — 5.6; 5.0; 4.1; 4.3 percentage of time in AF — p=0.520
N/A N=411 Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation
Heart Failure · Atrial Fibrillation
Primary: Composite of All-cause Mortality and Heart Failure Events — 50; 64 Participants
Phase 3 N=55 AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation
Atrial Fibrillation
Primary: Percent of Patients Free From AF and Off Class I and III Anti-arrhythmic Drugs as Determined by Holter Monitoring at 6 Months. — 74 percentage of subjects
N/A N=35 Prospective Elimination Of Distal Coronary Sinus-Left Atrial Connections for Atrial Fibrillation Ablation Trial
Atrial Fibrillation · Arrhythmias, Cardiac
Primary: Recurrence Rate of Atrial Arrhythmias — 8; 14; 7; 1 participants — p=0.047
N/A N=3,160 Exclusion of Intra-atrial Thrombus Before Catheter Ablation
Atrial Fibrillation · Thrombi
Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants
N/A N=107 The Dynamics of Human Atrial Fibrillation
Atrial Fibrillation · Atrial Tachyarrhythmia
Primary: Survival Free of Atrial Fibrillation — 28; 31 participants
N/A N=303 High-Density (HD) Wave Mapping in Subjects With Atrial Fibrillation as a Predictor of Recurrence After a Single Ablation Procedure Using a PVI-Only Strategy
Paroxysmal Atrial Fibrillation · Persistent Atrial Fibrillation · Cardiac Arrhythmia
Primary: Percentage of Subjects With One-year Success — 57.2 percentage of participants
N/A N=4,658 International Registry on Cardioversion of Atrial Fibrillation (MK-6621-051)
Atrial Fibrillation
Primary: Cardiovascular Disease History of Participants Presenting With Atrial Fibrillation at Baseline (Admission) — 1.3; 1.6; 1.4; 2.3 Percentage of Participants
Phase 4 N=396 TReatment of Atrial Fibrillation With Dual dEfibrillator in Heart Failure Patients
Heart Failure, Congestive
Primary: Unplanned Hospital Admissions for Cardiac Reasons OR Death of Cardiovascular Causes OR Progression to Chronic Atrial Fibrillation — 43; 44 participants
N/A N=269 Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With FIRM Guided Procedures
Persistent Atrial Fibrillation · Paroxysmal Atrial Fibrillation
Primary: Freedom From Atrial Fibrillation Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Recurrence at 12 Months Post Procedure. — 72; 76 Participants